ECOG EA3231 RAI-Refractory Thyroid Cancer with BRAF V600Em

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
EA3231, A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em (NCT06475989)
Principal Investigator
Headshot of Neal Edward Ready
Professor of Medicine
Protocol Number
IRB: PRO00117489
NCT: NCT06475989
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate